Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-22
Target enrollment:
Participant gender:
Summary
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter,
open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced
pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161
combined with PD-1 inhibitor (Nivolumab Injection).